Corinne Bauer, Ph.D., is a seasoned analytical leader with more than 20 years of scientific and managerial experience. She is deeply experienced in developing and implementing analytical strategies to analyze and characterize small molecules, polysaccharides, polypeptides, nanoparticles, as drug substance and drug product (oral, parenteral).
Corinne joined HiberCell from Sage Therapeutics where she led the analytical development effort for late phase compounds and helped bring ZulressoTM, the first FDA-approved treatment for postpartum depression, to market. She has spent most of her career working for small- to medium-sized pharmaceuticals and biotechnology companies, building teams of subject matter experts responsible for all analytical activities that support drug development and regulatory submissions.
Corinne received her M.Sc. from The City of Paris Industrial Physics and Chemistry Institution of Higher Education in France. She then earned her Ph.D. at the University of Science and Technology of Lille also in France.